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Abstract
Introduction
Developing guidelines to inform the use of antiretroviral pre-exposure prophylaxis (PrEP) for
HIV prevention in resource-limited settings must necessarily be informed by considering the
resources and infrastructure needed for PrEP delivery. We describe an approach that identi-
fies subpopulations of cisgender men who have sex with men (MSM) and transgender
women (TGW) to prioritize for the rollout of PrEP in resource-limited settings.
Methods
We use data from the iPrEx study, a multi-national phase III study of PrEP for HIV preven-
tion in MSM/TGW, to build statistical models that identify subpopulations at high risk of HIV
acquisition without PrEP, and with high expected PrEP benefit. We then evaluate empirically
the population impact of policies recommending PrEP to these subpopulations, and contrast
these with existing policies.
Results
A policy recommending PrEP to a high risk subpopulation of MSM/TGW reporting condom-
less receptive anal intercourse over the last 3 months (estimated 3.3% 1-year HIV inci-
dence) yields an estimated 1.95% absolute reduction in 1-year HIV incidence at the
population level, and 3.83% reduction over 2 years. Importantly, such a policy requires
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rolling PrEP out to just 59.7% of MSM/TGW in the iPrEx population. We find that this policy
is identical to that which prioritizes MSM/TGW with high expected PrEP benefit. It is esti-
mated to achieve nearly the same reduction in HIV incidence as the PrEP guideline put forth
by the US Centers for Disease Control, which relies on the measurement of more behavioral
risk factors and which would recommend PrEP to a larger subset of the MSM/TGW popula-
tion (86% vs. 60%).
Conclusions
These findings may be used to focus future mathematical modelling studies of PrEP in
resource-limited settings on prioritizing PrEP for high-risk subpopulations of MSM/TGW.
The statistical approach we took could be employed to develop PrEP policies for other at-
risk populations and resource-limited settings.
Introduction
Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)-based oral antire-
troviral regimens has been shown to be efficacious for preventing HIV acquisition in cisgender
men who have sex with men (MSM), transgender women (TGW), HIV serodiscordant hetero-
sexual couples, and people who inject drugs, with less consistent results among cisgender
women [1–7]. Low adherence is likely a major factor explaining the variable efficacy across
trial populations [8–10], although biological and behavioral factors may also play a role [11–
18].
PrEP delivery requires considerable public health infrastructure to maximize adherence
and to screen PrEP users regularly for renal safety, sexually transmitted infections (STIs), and
incident HIV infection to prevent PrEP use post-infection; drug resistance is also possible [1–
5]. With the licensing of oral co-formulated TDF and emtricitabine (FTC) (FTC-TDF) as
PrEP [19], the World Health Organization (WHO) and the US Centers for Disease Control
and Prevention (CDC) have disseminated guidelines for the use of PrEP for HIV prevention.
In developing such guidelines, the population incidence of HIV, expected PrEP effectiveness,
cost of medical care and infrastructure associated with PrEP delivery, and access to PrEP must
be considered. Furthermore, in resource-limited settings, policies that prioritize PrEP for select
subpopulations warrant consideration.
Inspired by the approaches to policy development and evaluation in other clinical contexts
[20–25], we used data from iPrEx, the largest PrEP efficacy trial to date in MSM/TGW, to
identify subpopulations of MSM/TGW who could be prioritized for PrEP rollout in resource-
limited settings. We relied on a decision-theoretic framework, under which the optimal policy
is that which maximizes population net benefit [26–32]. The optimal policy would recommend
PrEP to subpopulations with the highest absolute reduction in HIV incidence due to PrEP.
We call this a “PrEP-benefit-based policy”. We also considered a “risk-based” PrEP policy,
similar in concept to those put forth in the WHO and CDC guidelines [33, 34], which recom-
mends PrEP to individuals at high risk of HIV acquisition without PrEP. A risk-based policy
would achieve the same population impact as a PrEP-benefit based policy if the effect of PrEP
was a constant reduction in risk of HIV, i.e. if there was no modification of the PrEP effect
on the relative risk scale [28, 29, 35, 36]. Under this assumption, the reduction in absolute
HIV risk due to PrEP is proportional to risk of HIV without PrEP, and thus high-risk
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subpopulations have the largest absolute reduction in HIV incidence due to PrEP. This may be
the implicit assumption underlying the risk-based policies used in existing guidelines. If, how-
ever, demographic or risk behavior characteristics modify the relative risk associated with
PrEP, then subgroups at high risk of HIV without PrEP may not be those with the highest ben-
efit from PrEP. We evaluated both risk- and benefit-based PrEP policies to explore this possi-
bility. Specifically, we fit statistical models to the iPrEx data to identify both MSM/TGW
subpopulations at high risk of HIV acquisition without PrEP, and subpopulations with high
expected PrEP benefit. Next, we used these models to define risk- and PrEP-benefit-based poli-
cies, and determine the size of the MSM/TGW subpopulations who would be recommended
to take PrEP and the expected HIV incidence under each policy. We compared these data-
driven policies- optimized using the iPrEx data- to the existing PrEP guidelines in terms of
population impact. Using the iPrEx data, we estimated the population impact of policies
empirically- without reliance on modelling assumptions.
Mathematical modelling towards cost-effectiveness analysis has been the primary tool for
assessing the population impact of PrEP [37–42], but the modelling has not evaluated potential
prioritization based on data-driven statistical models of PrEP benefit or of HIV risk. Math-
model-based population impact estimates also rely on many assumptions, such as population
distributions of demographic characteristics, risk behaviours, and adherence, and on the asso-
ciations between these factors and PrEP efficacy. Empirical estimates of the impact of PrEP
policies, which do not rely on these assumptions, are lacking.
As for any analyses of randomized trial data, our results based on the iPrEx data pertain
directly to the population enrolled in the trial, and additional data are needed to inform on the
impact of PrEP policies for other populations. Of particular importance is adherence, since
data suggest that adherence in iPrEx was considerably lower than in subsequent open-label
and observational studies, and in settings where individuals are being provided an intervention
they know to be effective [4, 5, 43–50]. Future research will be needed to determine if the
impact estimates based on iPrEx generalize to populations with other distributions of adher-
ence, as well as different demographic and risk behavior characteristics. We elaborate on this
in the discussion.
Materials and methods
Ethics statement
The iPrEx study [1] was approved by the Committee on Human Research at the University of
California, San Francisco, as well as local institutional review boards at each study site: Comite´
Institucional de Bioe´tica, Asociacio´n Civil Impacta Salud y Educacio´n, Lima, Peru; Universi-
dad San Francisco de Quito, IRB #1, Quito, Ecuador; Fenway Community Health Institutional
Review Board, Boston, MA; Comissão de E´tica para Ana´lise de Projetos de Pesquisa, CAPPesq
Hospital das Clı´nicas da Faculdade de Medicina da USP, São Paulo, Brazil; Comitê de E´tica em
Pesquisa, Hospital Universitario Clementino Fraga Filho/Universidade Federal de Rio de
Janeiro, Rio de Janeiro, Brazil; Comitê de E´tica em Pesquisa do Instituto de Pesquisa Clı´nica
Evandro Chagas, Rio de Janeiro, Brazil; National IRB: Comissão Nacional de E´tica em Pes-
quisa–CONEP, Ministe´rio da Sau´de, Brası´lia, Brazil; University of Cape Town Research Ethics
Committee, Cape Town, South Africa; Human Experimentation Committee, Research Insti-
tute for Health Sciences, Chiang Mai, Thailand; Ethical Review Committee for Research in
Human Subjects, Department of Medical Services, Ministry of Public Health, Nonthaburi,
Thailand; Research Ethics Committee, Faculty of Medicine, Chiang Mai University, Chiang
Mai, Thailand. Written informed consent was obtained from each participant prior to enroll-
ment in the study.
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The iPrEx study
The iPrEx trial was a phase III study of FTC-TDF for HIV prevention; the results of the pri-
mary analysis of safety and efficacy were published by Grant et al. [1] Enrolment began in July
2007; participants were followed until November 2010. The trial is registered at ClinicalTrials.
gov and the clinical trial number is NCT00458393. The URL is https://clinicaltrials.gov/ct2/
show/NCT00458393.
iPrEx enrolled 2499 HIV-uninfected MSM and TGW who were randomized to placebo or
oral FTC-TDF once daily and followed for incident HIV infection. A total of 2442 participants
were included in our analysis (10 were HIV-infected at enrolment and 47 did not have a fol-
low-up HIV test). At November 21, 2010, median follow-up was 1.66 years (range: 0.07 to
3.30). The estimated efficacy of PrEP was 44% (p = 0.005). Eighty-three incident infections
occurred in the placebo arm, yielding an annual HIV incidence of 4.01% (95% confidence
interval [CI]: 2.89–5.08%). Forty-eight infections occurred in the FTC–TDF arm (annual HIV
incidence = 1.97%, 95% CI: 1.16–2.86%). Thus, PrEP was estimated to yield a 2.04% absolute
reduction in the 1-year rate of HIV infection (95% CI: 0.66%-3.55%, p = 0.003), corresponding
to a number needed to treat (NNT) of 49 participants treated per HIV infection event pre-
vented. The efficacy of PrEP on the relative risk scale was estimated to be 44% [1]. Sub-optimal
adherence among trial participants likely explains the modest efficacy [51].
Interviewer-administered or computer-assisted questionnaires were used to collect demo-
graphic and behavioral risk data on all participants at trial screening. Sexual risk-taking behav-
iours pertain to the prior 3 months; and exchange of sex for money, drugs, or services and self-
reported STIs cover the prior 6 months.
Risk and PrEP benefit modelling
We considered participants’ age, gender identity, and self-reported sexual risk behaviours at
baseline to predict HIV risk and PrEP benefit. Importantly, while demographic and risk
behaviour characteristics are frequently collected in clinical practice, measures of adherence
are not available before PrEP is actually provided. Accordingly, measures of adherence to
FTC-TDF were not included in our models of HIV risk or PrEP benefit. Categorical demo-
graphic/risk behaviour variables with less than two HIV cases per level were excluded to
improve model stability.
We used Cox proportional hazards logic regression models [52, 53] to select the individual
variables or combinations of variables that best predict risk of HIV infection without PrEP,
given data for participants on the placebo arm. We paired the fitted Cox model with a Nelson-
Aalen baseline hazard estimate [54] to estimate the cumulative HIV infection rate without
PrEP, denoted by Risk0(X), where X is a vector of baseline demographic and behavioral vari-
ables. We used the same approach to predict HIV risk under PrEP using data from the
FTC-TDF arm, denoted by Risk1(X). We calculated PrEP benefit as the difference in HIV risk
without vs. with PrEP, Δ(X) = Risk0(X) − Risk1(X). Cross-validation was used to select the tun-
ing parameters for the logic regression models. To assess model stability, models were re-fit in
500 bootstrap samples. Further details are summarized in supplementary materials, S1
Methods.
PrEP policies
We first considered the policy that maximizes net benefit, which recommends PrEP to individ-
uals with a high expected benefit from PrEP as measured by Δ(X) = Risk0(X)–Risk1(X) [26–
32]. The optimal threshold of PrEP benefit above which PrEP is recommended corresponds to
the inverse of the threshold number needed to treat–the maximum number of individuals one
Recommending PrEP to subpopulations based on risk characteristics
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is willing to treat to prevent one HIV infection [55–57]. We focused primarily on a threshold
of 1.2%, after considering the null hypothesis used to design iPrEx and other PrEP efficacy tri-
als [1, 2, 6]. The null hypothesis codifies the design assumptions about the NNT to make PrEP
clinically useful. Specifically, a null of 30% PrEP efficacy and 4.0% 1-year HIV incidence in the
placebo group implies that 1.2% is the smallest absolute reduction in 1-year HIV incidence
due to PrEP that would justify PrEP for HIV prevention. The 1.2% threshold corresponds to
an NNT of 83. We also considered the effect of different PrEP benefit thresholds.
The second type of PrEP policy we considered was motivated by current WHO guidelines,
which suggest considering PrEP for sub-populations with 3 or more HIV infections per 100
person-years at risk [58]. When there is no modification of the PrEP effect on the relative risk
scale, an individual’s level of PrEP benefit, Δ(X) = Risk0(X)–Risk1(X), is proportional to their
risk of HIV without PrEP, Risk0(X)–and therefore high-risk individuals have the largest PrEP
benefit. However, if this assumption does not hold, due to effect modification on the relative
risk scale, a risk-based policy may have less population impact than a PrEP-benefit based pol-
icy. We evaluated a risk-based policy, which recommends PrEP to individuals with a 1-year
HIV risk of 3% or more, consistent with the WHO guidelines. We compared this policy to the
US CDC PrEP guidelines for MSM that recommends PrEP on the basis of 7 demographic and
risk factors including number of male partners and condomless intercourse [33] (Table 1),
and to the PrEP-benefit based policy defined above. The guidelines are based on a clinical
screening index that was developed using data from VAXGEN 004, an HIV vaccine trial
among MSM in the US [59, 60], and validated using data from Project Explore, an HIV behav-
ioral intervention trial among US MSM [61].
Evaluating population impact
We used existing methods to assess the population impact of PrEP policies [62–65]. Each pol-
icy was first evaluated by the proportion of individuals recommended PrEP by the policy-
Table 1. US CDC recommended indications for use of PrEP among MSM [33] and methods used to determine
associated PrEP recommendations for iPrEx trial participants, given baseline demographic and risk behaviour
dataa.
CDC criterion Criterion met for iPrEx participants?
Adult man Yes, considered satisfied for all participantsb
Without acute or established HIV infection Yes, all participants
Any male sex partners in last 6 months Yes, all participants
Not in a monogamous partnership with a recently-tested,
HIV-negative man
Yes if > 1 male partner OR HIV-positive partner in
last 3 months
AND at least one of the following:
Any anal sex without a condom in last 6 months Yes if condomless intercourse in last 3 months
Any STI diagnosed or reported in last 6 months Yes if STI reported in last 6 months OR seropositive
for syphilis
Is in an ongoing sexual relationship with an HIV-positive
male partner
Yes if HIV-positive partner in last 3 months
MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.
aAt screening, iPrEx participants were asked about sexual risk-taking behaviours over the prior 3 months. Questions
about exchange of sex for money, drugs, or services and self-reported sexually transmitted infections (STIs) covered
the last 6 months.
bCDC guidelines do not specify special considerations for TGW. Therefore, we applied the same criteria to both
MSM and TGW in iPrEx.
https://doi.org/10.1371/journal.pone.0222183.t001
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namely, the proportion of iPrEx participants with demographic and risk behaviour character-
istics that would yield a PrEP recommendation under the policy, estimated by pooling across
the two treatment arms. This metric is a proxy for the resource-utilization of the policy. Sec-
ond, we evaluated the expected cumulative HIV infection rate under the policy empirically:
the Kaplan-Meier method [66] was used to estimate the HIV infection rate among iPrEx par-
ticipants in the PrEP arm who would be recommended PrEP by the policy, and to estimate the
HIV rate among iPrEx participants in the placebo arm who would not be recommended PrEP
by the policy. The two estimates were combined using a weighted average, where the weights
were determined by the proportion of iPrEx participants who would be recommended PrEP
by the policy. Empirical estimation of policy impact is appealing in that it does not require
modeling assumptions, and it is made possible by the randomized and placebo-controlled
nature of the iPrEx design. Specifically, the randomized trial design ensures that the difference
in HIV incidence between the PrEP and placebo groups can be attributed to PrEP itself- rather
than to differences in risk taking behaviors or exposure to HIV between the groups. Point esti-
mates and bootstrap-based confidence intervals were bias-corrected to account for having
used the same data to predict risk/PrEP benefit and to evaluate population impact. See S1
Methods for details.
Results
Univariate associations with HIV infection and PrEP efficacy
Most iPrEx participants [1, 67] were cisgender male (87%) and aged 18–24 (50%) (Table 2).
The most frequently reported risk behaviours were insertive or receptive condomless anal
intercourse (86%) and more than 5 male sex partners (56%) over the last 3 months. The stron-
gest univariate predictors of increased HIV risk without PrEP were cocaine use over the last
month (hazard ratio (HR) 2.58 [95% CI: 1.19–5.62]) and condomless intercourse over the last
3 months (HR 1.23 [95% CI: 0.32–4.62] for insertive only; HR 4.14 [95% CI: 1.28–13.4] for
receptive only; 5.11 [95% CI: 1.56–16.74] for receptive and insertive). These variables were also
the strongest univariate predictors of increased PrEP efficacy, although, notably, none were
statistically significant modifiers of efficacy (Table 2).
Model for risk of HIV without PrEP
The best Cox proportional hazards logic regression model for predicting HIV infection risk
without PrEP is shown in Table 3. Individuals who report engaging in condomless receptive
anal intercourse over the last 3 months, without insertive (HR = 3.59 [95% CI: 1.84–6.98]) or
with insertive anal intercourse (HR = 4.43 [95% CI: 2.23–8.81]) were estimated to be at consid-
erably increased risk. As shown in Fig 1A, individuals reporting either behaviour were esti-
mated to have a 1-year HIV infection risk above 3%, and were thus recommended PrEP under
the risk-based policy (59.7% of individuals); the remaining 40.3% of individuals were not rec-
ommended PrEP under this policy. The risk model itself was reasonably stable across boot-
strap samples; the condomless receptive intercourse and condomless receptive and insertive
intercourse variables were selected in 342 and 364 of the 500 models fit to bootstrapped data-
sets, respectively (S1 Fig). More importantly, the risk-based PrEP recommendations were
highly stable, with 40% of individuals recommended PrEP in 70% or more bootstrap samples
and the other 60% not recommended PrEP in 89% or more samples (S4 Fig).
For comparison, we developed risk models using alternative model-building and machine-
learning approaches. The best stepwise Cox proportional hazards regression model was identi-
cal to that built using Cox logic regression (S1 Table) and had similar population impact; small
differences appeared between models in bootstrapped datasets (S2 Table and S2 Fig). Using
Recommending PrEP to subpopulations based on risk characteristics
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Table 2. Distributions of demographic and risk behavior variables by treatment arm and their univariate associations with HIV infection risk and PrEP efficacy.
Estimated HIV incidence per 100 person-years is reported. The hazard ratio (“risk factor HR”) for each variable quantifies the association between the variable and HIV
infection risk, within each treatment arm. The PrEP HR (FTC-TDF vs. Placebo) quantifies the efficacy of PrEP for each level of each variable. The ratio of PrEP HRs quan-
tifies the association between the variable and PrEP efficacy. A Wald test of interaction is reported for each variable.
Placebo (N = 1218) FTC-TDF
(N = 1224)
N Infections
(N)
HIV
Incidence
Risk
Factor
HR
(95% CI)
N Infections
(N)
HIV
Incidence
Risk
Factor
HR
(95% CI)
PrEP
HR
Ratio of
PrEP HRs
(95% CI)
P-value for
Interaction
Gender Cisgender male 1060 73 0.04 - 1063 38 0.02 - 0.52 - 0.183
Transgender
female
158 10 0.04 0.9 (0.46,
1.74)
161 10 0.04 1.69
(0.84,
3.4)
0.96 1.88 (0.72,
4.91)
Age 18–24 644 47 0.04 - 578 30 0.03 - 0.72 - 0.202
25–29 234 15 0.04 0.88
(0.49,
1.57)
266 11 0.02 0.75
(0.37,
1.49)
0.62 0.85 (0.35,
2.1)
> = 30 340 21 0.04 0.82
(0.49,
1.38)
380 7 0.01 0.34
(0.15,
0.78)
0.3 0.42 (0.16,
1.1)
Education Secondary or
less
678 42 0.04 - 693 30 0.02 - 0.7 - 0.169
Post-secondary 529 41 0.05 1.3 (0.85,
2.01)
515 17 0.02 0.79
(0.44,
1.44)
0.42 0.61 (0.29,
1.27)
Missing 11 16 -
Race White 201 9 0.03 - 221 3 0.01 - 0.3 - 0.790
Black/
African
American
93 6 0.05 1.54
(0.55,
4.32)
112 4 0.03 2.98
(0.67,
13.31)
0.58 1.94 (0.31,
11.94)
Mixed/
Other
857 65 0.04 1.33
(0.66,
2.68)
828 39 0.02 2.55
(0.78,
8.27)
0.61 1.91 (0.49,
7.53)
Asian 67 3 0.04 1.4 (0.38,
5.2)
63 2 0.03 3.31
(0.55,
19.92)
0.71 2.36 (0.26,
21.79)
Cocaine use in past
month
None 1165 76 0.04 - 1147 47 0.02 - 0.63 - 0.067
Cocaine 53 7 0.1 2.58
(1.19,
5.62)
77 1 0.01 0.38
(0.05,
2.74)
0.09 0.15 (0.02,
1.23)
HIV-positive partner
in last 3 months
None 1109 76 0.04 - 1122 45 0.02 - 0.59 - 0.708
> 1 109 7 0.04 1.14
(0.52,
2.47)
102 3 0.02 0.92
(0.29,
2.98)
0.47 0.81 (0.2,
3.31)
Unprotected sex in
last 3 months
None 174 3 0.01 - 184 6 0.02 - 1.92 - 0.143
Insertive only 310 8 0.01 1.23
(0.32,
4.62)
317 8 0.01 0.63
(0.22,
1.83)
1.04 0.52 (0.09,
2.82)
Receptive only 430 41 0.05 4.14
(1.28,
13.4)
437 17 0.02 0.86
(0.34,
2.19)
0.54 0.21 (0.05,
0.93)
Receptive and
insertive
304 31 0.06 5.11
(1.56,
16.74)
286 17 0.03 1.43
(0.56,
3.64)
0.41 0.28 (0.06,
1.27)
(Continued)
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Cox regression model with lasso, the best-predicting model involved many more variables (S1
Table) but had a similar estimated impact (S2 Table) and was much less stable across bootstrap
samples (S3 and S4 Figs).
Model for PrEP benefit
The best Cox proportional hazards logic regression model for predicting HIV infection risk
with PrEP is shown in Table 3. Individuals under age 30 (HR 2.78; 95% CI: 1.25–6.21) and
Table 2. (Continued)
Placebo (N = 1218) FTC-TDF
(N = 1224)
N Infections
(N)
HIV
Incidence
Risk
Factor
HR
(95% CI)
N Infections
(N)
HIV
Incidence
Risk
Factor
HR
(95% CI)
PrEP
HR
Ratio of
PrEP HRs
(95% CI)
P-value for
Interaction
Number of male
sexual partners in last
3 months
1 98 5 0.03 - 108 4 0.02 - 0.73 - 0.892
2 to 5 450 26 0.03 1 (0.38,
2.6)
411 11 0.02 0.71
(0.23,
2.23)
0.5 0.71 (0.16,
3.17)
> 5 670 52 0.04 1.28
(0.51,
3.2)
705 33 0.03 1.05
(0.37,
2.98)
0.58 0.83 (0.21,
3.31)
Any transactional sex
in last 6 months
No 721 49 0.04 - 717 24 0.02 - 0.49 - 0.339
Yes 497 34 0.04 0.88
(0.57,
1.37)
507 24 0.03 1.22
(0.69,
2.16)
0.7 1.39 (0.68,
2.84)
Any self-reported STI
in last 6 months
No 910 54 0.04 - 891 33 0.02 - 0.63 - 0.466
Yes 308 29 0.05 1.37
(0.87,
2.16)
333 15 0.02 1.02
(0.55,
1.87)
0.47 0.74 (0.35,
1.58)
Seropositive for
syphilis at baseline
No 1056 65 0.04 - 1057 40 0.02 - 0.62 - 0.427
Yes 162 18 0.06 1.64
(0.97,
2.78)
167 8 0.03 1.12
(0.52,
2.4)
0.42 0.68 (0.27,
1.71)
CI, confidence interval; HR, hazard ratio; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection; FTC-TDF, emtricitabine/tenofovir disoproxil fumarate
https://doi.org/10.1371/journal.pone.0222183.t002
Table 3. The best Cox proportional hazards logic regression models for predicting HIV infection risk without PrEP (fit using placebo arm data) and with PrEP (fit
using FTC-TDF arm data). For each baseline demographic or risk behaviour variable entering in the model, the associated hazard ratio (HR) for HIV infection is shown.
Without PrEP (Placebo Arm) With PrEP (FTC-TDF Arm)
Baseline demographic/risk behaviour variable HR
(95% CI)
p-value Baseline demographic/risk behaviour variable HR
(95% CI)
p-value
Condomless receptive only anal intercourse in last 3
mo.
3.59 (1.84–
6.98)
0.0002 Younger than 30 yrs. 2.78 (1.25–
6.21)
0.013
Condomless receptive and insertive anal intercourse in
last 3 mo.
4.43 (2.23–
8.81)
<
0.0001
Condomless receptive and insertive anal intercourse in
last 3 mo.
1.87 (1.04–
3.40)
0.037
CI, confidence interval; HR, hazard ratio; PrEP, pre-exposure prophylaxis; FTC-TDF, emtricitabine—tenofovir disoproxil fumarate.
https://doi.org/10.1371/journal.pone.0222183.t003
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who reported condomless receptive and insertive anal intercourse over the last 3 months (HR
1.87; 95% CI: 1.04–3.40) were estimated to be at increased risk with PrEP. By combining this
with the model for HIV risk without PrEP, a model for PrEP benefit as a function of age and
condomless intercourse was obtained. However, although age predicts some variation in the
level of PrEP benefit (S4 Fig), only condomless intercourse determines the PrEP recommenda-
tion under the PrEP-benefit-based policy with a benefit threshold of 1.2%: individuals report-
ing condomless receptive or insertive and receptive anal intercourse are predicted to have at
Fig 1. Risk-based PrEP policy and HIV infection risk by PrEP recommendation. Flowchart for determining PrEP
recommendation for an individual MSM/TGW under the risk-based policy, which is based on a model for HIV
infection risk without PrEP fit to the iPrEx data (A). Empirical estimates of the size of each subpopulation and of the
1-year HIV infection risk without PrEP in each subpopulation are also shown. The PrEP-benefit policy developed
using the iPrEx data and using a PrEP benefit threshold of 1.2% is identical. Cumulative rate of HIV infection over
time, by treatment arm and risk-based PrEP recommendation, with pointwise 95% confidence intervals (B).
https://doi.org/10.1371/journal.pone.0222183.g001
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least a 1.2% reduction in 1-year HIV infection risk due to PrEP, and are recommended PrEP
under the policy (59.7% of individuals). Importantly, therefore, this PrEP-benefit-based policy
recommends PrEP to the same subpopulation as does the risk-based policy.
We explored the use of an alternative PrEP benefit threshold; few thresholds could be exam-
ined given that the PrEP benefit model only predicts six levels of PrEP benefit (for three levels
for type of condomless intercourse and two levels of age). Using a lower PrEP benefit threshold
of 0.7%—corresponding to a 0.7% lower 1-year risk of HIV with PrEP and an NNT of 143—
would result in recommending PrEP to individuals who report condomless receptive or inser-
tive and receptive anal intercourse or who are 30 years or older (S4 Fig), an estimated 71% of
the iPrEx population.
We found that the PrEP benefit model and associated PrEP-benefit-based PrEP recommen-
dations were less stable across bootstrap samples than their risk-based counterparts (S5 Fig).
Alternative modelling approaches did not yield policies with improved performance (S2
Table).
Population impact of PrEP policies
Fig 1B shows the estimated cumulative rates of HIV infection over time by treatment arm, for
subpopulations of MSM/TGW who would or would not be recommended PrEP under the
risk-based policy. The policy is estimated to achieve a 1.95% 1-year HIV infection rate (95%
CI: 1.21%-2.73%), below the 1.97% achieved if PrEP is recommended to all MSM/TGW in the
iPrEx population (95% CI: 1.16%-2.86%) (Table 4). Strikingly, the policy would require treat-
ing just 59.7% of MSM/TGW (95% CI: 24.9%-100%). The benefit of PrEP in the high-risk sub-
group is an absolute 3.31% reduction in 1-year HIV incidence (95% CI: 1.20%-6.12%),
corresponding to an NNT of 30 –as opposed to a policy of PrEP for all MSM/TGW which has
an NNT of 49.
Table 4 also shows the estimated population impact of the PrEP-benefit-based policy that
uses a PrEP benefit threshold of 1.2%. Since this PrEP-benefit-based policy is identical to the
risk-based policy, the estimated impact of the two policies is similar; minor differences
between the models occur in some bootstrap samples, with the latter model being more vari-
able. Using a lower PrEP benefit threshold of 0.7% would result in more individuals being rec-
ommended PrEP (71.0% vs. 59.7%) and similar HIV infection rates at 1 and 2 years.
The estimated impact of the CDC guideline is shown in Table 4 as well. This guideline is
estimated to recommend PrEP to a larger subpopulation of MSM/TGW than the risk-based
policy (86.4% vs. 59.7%), and yet it is estimated to achieve a very similar estimated 1-year HIV
infection rate (1.97% vs. 1.95%). However, it should be noted that the confidence interval for
the proportion of the population to be recommended PrEP under the risk-based policy is
wide, and does not rule out the possibility that the policy recommends PrEP to the same-sized
subpopulation as the CDC guideline. The confidence intervals for risk- and PrEP-benefit
based policies, which are derived using the iPrEx data, are wide because they account for the
uncertainty in the risk- and PrEP-benefit models. In contrast, the CDC policy is fixed, having
been derived using historical data, and therefore the size of the subpopulation to be recom-
mended PrEP is estimated much more precisely. Separate data will be needed to validate the
apparent difference in resource-utilization of the risk- and CDC policies.
Contrasting PrEP policies
Although a PrEP-benefit-based policy has theoretical appeal, the risk-based policy and PrEP-
benefit-based policy (1.2% threshold) that we developed using the iPrEx data were found to be
identical, and therefore have similar estimated population impact (Table 4). Fig 2 highlights
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this visually, showing the estimated 1- and 2-year HIV infection rates achieved using the poli-
cies and the estimated rate under a policy that recommends PrEP to all. The very similar per-
formance of the risk- and PrEP-benefit-based policies reflects the fact that there are not strong
interactions between PrEP and baseline demographic and risk behaviour variables, and sug-
gests that an individual’s risk of HIV without PrEP is all that is needed to identify individuals
with high absolute reduction in HIV risk due to PrEP. Coupled with the fact that the risk-
based policy is more stable across bootstrap samples, we view the risk-based policy as having
greater potential.
These results do identify an important difference between the risk-based policy optimized
using iPrEx data and the CDC guideline. While both policies achieve nearly the same HIV
incidence as PrEP for all MSM/TGW, the CDC guideline is estimated to recommend PrEP to
a larger subpopulation of MSM/TGW (Fig 2). An estimated 28.9% of individuals would be rec-
ommended PrEP by the CDC guideline but not by the risk-based policy, and another 2.2%
would not be recommended PrEP by the CDC guideline but would by the risk-based policy
(S3 Table). Importantly, the CDC guidelines are based on previous studies of HIV risk factors
among US MSM in HIV prevention trials [59–61]. These results suggest that the CDC guide-
lines may be broader than they need to be to achieve a substantial reduction in HIV incidence.
It may be of interest to compare the HIV incidence achieved under policies that are con-
strained to use the same resources, i.e. to treat a subpopulation of the same size. However, such
policies are difficult to examine with the risk and PrEP benefit models fit to the iPrEx data; the
fitted risk model takes only three levels and the PrEP benefit model takes six levels and
Table 4. Estimated impact of risk-based, PrEP benefit-based, and CDC PrEP policies for the MSM/TGW population. Policies are ordered by the associated propor-
tion of the population that is recommended PrEP. Impact is shown over 1 and 2 years post-enrolment.
Proportion
recommended PrEP
(95% CI)
Reduction in HIV incidence in
subpopulation recommended PrEP
(95% CI)
HIV incidence
under policy (95%
CI)
Reduction in HIV incidence in
subpopulation recommended PrEP
(95% CI)
HIV incidence
under policy (95%
CI)
1 year post-enrolment 2 years post-enrolment
PrEP for
none
0% – 4.01 – 7.75
(2.89–5.08) (5.95–9.50)
Risk-based 59.7 3.31 1.95 5.53 3.83
policy (24.9–100) (1.20–6.12) (1.21–2.73) (2.55–12.8) (2.67–5.43)
PrEP-
benefit-
59.7 3.11 2.07 5.30 4.05
based policy
(1.2%
(26.1–95.5) (1.45–5.50) (1.28–3.10) (2.58–8.83) (2.84–6.62)
threshold)
PrEP-
benefit-
71.0 2.84 1.94 4.30 4.36
based policy
(0.7%
(36.7–100) (1.37–5.12) (1.18–2.76) (2.40–8.77) (2.75–5.82)
threshold)
CDC
guideline
86.4 2.32 1.97 4.04 4.47
(85.0–87.6) (0.75–3.92) (1.11–2.91) (1.83–6.29) (3.00–6.15)
PrEP for all 100% 2.04 1.97 3.91 3.84
(0.66–3.55) (1.16–2.86) (1.62–6.03) (2.57–5.10)
CDC, Centers for Disease Control and Prevention; CI, confidence interval; PrEP, pre-exposure prophylaxis.
https://doi.org/10.1371/journal.pone.0222183.t004
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therefore the size of the subpopulations treated cannot be controlled with precision. In particu-
lar, employing anything lower than the 3% high risk threshold we used would mean PrEP is
recommended to the entire MSM/TGW population. Using a lower PrEP benefit threshold of
0.7% would result in a PrEP-benefit-based policy that recommends PrEP to a similar fraction
of the population as does the CDC guideline (71% vs. 86%), and the estimated HIV incidences
under these two policies are highly similar (Table 3).
Point estimates suggest that all of these PrEP policies may have declining impact over time
(Fig 3), especially the CDC guideline. This result is somewhat expected, given that the predic-
tive capacity of the baseline risk behaviour variables may diminish with time.
Population impact under higher adherence
Data suggest that adherence to PrEP may be higher in "real world" contexts, where individuals
know that PrEP is effective and that they are in fact receiving it, as opposed to being blinded to
Fig 2. Contrasting PrEP policies with a policy that recommends PrEP to all individuals. Policies are contrasted in terms of the proportion of individuals
recommended PrEP by the policy (x-axis) and the estimated 1- and 2-year HIV infection rates under the policy (y-axis). Symbols show the estimated 1- and 2-year
infection rates and lines show 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0222183.g002
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PrEP vs. placebo receipt, as in the iPrEx study [4, 5, 43–50]. In addition, many analyses have
shown that PrEP efficacy is strongly associated with adherence [51, 68–70]. Therefore, it is of
interest to determine whether the impact of the PrEP policies we examine would differ in set-
tings with higher adherence. We conducted a simple sensitivity analysis to address this ques-
tion. Specifically, we examined scenarios where we assumed that the relative risk associated
with PrEP was reduced by a factor of 1.0 to 0.1, due to improved adherence relative to that
seen in the iPrEx study. This corresponds to varying the overall PrEP relative-risk from 0.56
(the observed relative risk) to 0.06. A key limitation of this sensitivity analysis is that there are
no data we know of to inform on whether the same decrease in PrEP relative risk would apply
equally to all subgroups of the MSM/TGW population, or whether some subgroups would
have greater decreases in PrEP relative risk than others due to better adherence. Because nei-
ther study-level meta-analyses associating efficacy with adherence [69, 70] nor analyses of effi-
cacy among adherers in individual trials [51, 68] inform on this, for simplicity we assume that
the same multiplicative decrease in PrEP relative risk applies to the iPrEx population at large,
as well as to the high risk subgroup identified by our risk-based PrEP policy and the high risk
subgroup identified by the CDC policy.
Fig 3. HIV infection risk over time under risk-based, PrEP-benefit based, and CDC PrEP policies. Cumulative rate of HIV infection over time with pointwise 95%
confidence intervals. The PrEP-benefit-based policy uses a PrEP benefit threshold of 1.2%.
https://doi.org/10.1371/journal.pone.0222183.g003
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Fig 4 shows the results of this sensitivity analysis. We make two observations. First, as
expected, as the PrEP relative risk decreases, the HIV infection rate achieved under all policies
decreases. Second, as the PrEP relative risk decreases, the PrEP for all policy has a more rapid
decline in HIV infection rate than do the risk-based and CDC policies. This is because the lat-
ter two policies recommend PrEP to just 59.7% and 86.4% of the MSM/TGW population,
respectively, and so the reduction in HIV due to PrEP only affects these subpopulations. Note
that the size of the subpopulations recommended PrEP does not change across the scenarios
examined here. These results suggest that risk-based policies may have less appeal in settings
with higher adherence. We caution, however, that these results are a direct consequence of our
assumption that the multiplicative reduction in PrEP relative risk is the same across all sub-
populations. A more comprehensive modeling approach- if informed by data on how efficacy
changes as a function of adherence in different subgroups of the population- could more effec-
tively compare the impact of different PrEP policies while allowing for different patterns of
adherence.
Fig 4. Sensitivity analysis: HIV infection rate under PrEP for all, risk-based, and CDC PrEP policies, with varying PrEP relative risk. Cumulative 1- and 2-year
HIV infection rates under each policy, as a function of the multiplicative reduction in PrEP relative risk due to increasing adherence. An 0.9 multiplicative reduction in
PrEP relative risk reduces the relative risk from 0.56 to 0.50. Pointwise 95% confidence intervals are shown with shading.
https://doi.org/10.1371/journal.pone.0222183.g004
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Discussion
We analysed data from a landmark multi-national PrEP efficacy study in MSM/TGW to iden-
tify subpopulations predicted to be at high HIV risk without PrEP and subpopulations with
high expected PrEP benefit. Based on these models, we defined risk-based and PrEP-benefit
based policies for prioritizing PrEP, and evaluated and compared the policies empirically, in
terms of the size of the subpopulation recommended PrEP under each policy and the expected
HIV incidence under each policy. We found the risk- and PrEP-benefit-based policies to have
similar estimated impact in the MSM/TGW population in iPrEx, consistent with our analyses
and prior work suggesting that the PrEP effect was relatively constant on the relative risk scale,
i.e. there was no strong effect modification [1, 67]. We compared the risk-based policy derived
using the iPrEx data to the CDC PrEP guideline for MSM, and estimated that it would priori-
tize PrEP to a smaller subpopulation while achieving a similar reduction in HIV incidence.
Risk-based prioritization of PrEP appears to be a resource-efficient strategy for resource-lim-
ited settings, achieving nearly the same reduction in HIV incidence as does rolling out PrEP
for all MSM/TGW.
Critically, our results pertain directly only to the MSM/TGW population from which iPrEx
participants were recruited. The demographic and risk behaviours that best predict HIV risk
may differ in other populations. The impact of the iPrEx-derived risk-based policy may not
generalize to other populations, either because the distribution of demographic and risk char-
acteristics differs, or because the level of PrEP efficacy differs. For example, recent studies of
Black American MSM and young MSM have found HIV incidence exceeding the iPrEX rates
[71, 72]. In the PROUD open-label PrEP study [5], PrEP efficacy was estimated at 86%, much
higher than in iPrEx. As illustrated by our sensitivity analysis, in settings where larger subpop-
ulations are high risk and prioritized for PrEP, or where PrEP efficacy is higher, we may expect
to see smaller resource savings of a risk-based PrEP policy as compared to a policy of PrEP for
all.
Given that the iPrEx study was an individually-randomized trial, these results only charac-
terise the impact of PrEP policies attributable to the direct effect of PrEP (as opposed to the
total effect [73]). The duration of iPrEx follow-up also only permits estimation of impact over
1–3 years of follow-up. The reliability of the risk behaviour variables may also differ in iPrEx as
opposed to more routine clinical settings [74–76].
The risk-based PrEP policy optimized using iPrEx data would recommend PrEP to MSM/
TGW who report engaging in condomless receptive anal intercourse, or condomless receptive
and insertive anal intercourse. However, a meaningful benefit of PrEP cannot be ruled out for
MSM/TGW who engage in exclusively insertive anal intercourse. For example, there may be
individual factors, such as an HIV-infected partner who is not virally suppressed, that would
clearly lend themselves to a recommendation for PrEP. Providers must base their prescribing
practices on individual- rather than population-level impact.
Mathematical modelling is and will continue to be essential for PrEP policy research. Using
mathematical models allows researchers to study and isolate the influence of factors such PrEP
uptake and adherence on population impact. Modeling can also integrate multiple sources of
data, e.g. population distributions of demographic and risk behaviours, as opposed to distribu-
tions among individuals eligible for and willing to enrol in clinical trials. Modeling can capture
both direct and indirect effects of PrEP, examine impact over longer time periods, and for-
mally incorporate assumptions about the cost of providing PrEP. However, model-based esti-
mates of PrEP impact are only as reliable as their data inputs and underlying assumptions.
Mathematical models of PrEP impact typically assume the existence of subpopulations with
different behaviors and levels of HIV risk, that PrEP reduces risk by a factor that is constant
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across risk groups, and that adherence increases PrEP efficacy by a constant amount across
risk groups. We posit that PrEP efficacy trials, which have limited generalizability but which
enable population impact to be estimated directly using observed data, can highlight policies
for further investigation and provide preliminary estimates of population impact, thus comple-
menting the modelling and contributing to policy discussions.
Buchbinder and colleagues [67] previously analysed the iPrEx trial data to assess the base-
line demographic and risk behaviour variables individually for their ability to predict HIV
infection risk without PrEP (in the placebo arm), and the population attributable fraction and
NNT were calculated for risk behaviour subgroups. Two variables, condomless insertive or
receptive anal intercourse, and condomless receptive anal intercourse with a partner of
unknown HIV serostatus, were identified as being most important for prioritizing PrEP roll-
out. Our analyses went further to build multivariate models to predict not only HIV infection
risk without PrEP, but also to model PrEP benefit as a function of demographic and risk
behavior variables. The first variable identified by [67], but not the second, was selected into
our multivariate risk- and PrEP-benefit models, and forms the basis for our associated risk-
based PrEP policy. We also evaluated PrEP policies based on our multivariate risk- and PrEP-
benefit models, using measures that directly characterize the population impact of the policies:
the proportion of the population recommended PrEP, and the reduction in HIV incidence
under the policy.
Zheng et al. [77] recently put forth statistical methods for developing PrEP policies for
resource-limited settings, based on criteria for maximizing the proportion of would-be HIV-
infected subjects absent PrEP who are identified and recommended PrEP (i.e. sensitivity) sub-
ject to a cost constraint (fraction of population treated), or based on minimizing cost subject
to a fixed sensitivity. Policies were evaluated in terms of sensitivity and the number needed to
test to detect one HIV infection, using survey data from Eastern Uganda. Instead, given ran-
domized trial data, we evaluate policies in terms of their impact on HIV incidence. Further-
more, the risk- and benefit-based policies we consider are grounded in decision theory and are
designed to maximize the net benefit of a policy.
Conclusions
We conclude that risk-based policies that prioritize PrEP for MSM/TGW subpopulations at
highest risk of HIV without PrEP are worth further investigation for resource-limited settings.
Risk-based policies are easy to understand and interpret and we did not find greater impact of
policies that prioritize based on expected PrEP benefit. The existing CDC guideline, which
requires measurement of 7 demographic and risk factors including number of male partners
and condomless intercourse, or our more parsimonious risk model that is based only on con-
domless intercourse, could be the focus of future policy research for the MSM and TGW popu-
lation. Our statistical approach could be used to explore and evaluate PrEP policies for other
populations.
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